RiboX Therapeutics
RXIM002 uses targeted LNPs carrying CD19 CAR circular RNA. The August 2026 update reports ongoing China IIT follow-up and FDA IND clearance for autoimmune cytopenias. It also discloses a fatal serious adverse event in a participant with systemic sclerosis; causality should not be inferred.
Corporate information
- Company entity
- RiboX Therapeutics
- Headquarters / principal office
- No verified public location identified
- Founded
- 2021 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.riboxtx.com/news/new_attention.html ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
RXIM002 uses targeted LNPs carrying CD19 CAR circular RNA. The August 2026 update reports ongoing China IIT follow-up and FDA IND clearance for autoimmune cytopenias. It also discloses a fatal serious adverse event in a participant with systemic sclerosis; causality should not be inferred.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- RiboX Therapeutics — official page checked November 4, 2026
- Founding / incorporation disclosure — scope stated in field